NCT01248442

Brief Summary

In this placebo controlled study the investigators aim to investigate the effect of a 3 month vitamin D supplementation on parameters of the immune, endocrine and metabolic system in healthy women and men. Vitamin D. In a pilot study the investigators showed an increase of certain immune cells, which regulate immunotolerance, the investigators therefore try to confirm these results with a placebo group. Furthermore the investigators assess the effect of vitamin D on the glucose metabolism and hormone levels.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Nov 2009

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2009

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2010

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

November 24, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 25, 2010

Completed
Last Updated

February 9, 2012

Status Verified

February 1, 2012

Enrollment Period

7 months

First QC Date

November 24, 2010

Last Update Submit

February 8, 2012

Conditions

Keywords

Vitamin D DeficiencyAutoimmune diseaseDiabetes

Outcome Measures

Primary Outcomes (1)

  • Increase and function of peripheral regulatory T-cells

    The level and function of the regulatory T-cells will be compared between the two groups.

    3 months

Secondary Outcomes (4)

  • immunophenotyping

    3 months

  • Renin and aldosterone concentrations

    3 months

  • Insulin secretion

    3 months

  • calcium levels

    3 months

Study Arms (2)

Cholecalciferol

EXPERIMENTAL
Drug: Cholecalciferol

Placebo

PLACEBO COMPARATOR
Drug: Placebo

Interventions

monthly dose of 140.000 IU of cholecalciferol orally, 3 times.

Also known as: Oleovit D3
Cholecalciferol

Matching Placebo

Also known as: Almondoil
Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>= 10 years
  • healthy subjects without chronic disease

You may not qualify if:

  • Hypercalcemia \>2,65 mmol/L
  • pregnancy and lactation period
  • acute infections
  • chronic disease requiring treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University Graz

Graz, 8036, Austria

Location

Related Publications (1)

  • Prietl B, Treiber G, Mader JK, Hoeller E, Wolf M, Pilz S, Graninger WB, Obermayer-Pietsch BM, Pieber TR. High-dose cholecalciferol supplementation significantly increases peripheral CD4(+) Tregs in healthy adults without negatively affecting the frequency of other immune cells. Eur J Nutr. 2014 Apr;53(3):751-9. doi: 10.1007/s00394-013-0579-6. Epub 2013 Sep 3.

MeSH Terms

Conditions

Vitamin D DeficiencyAutoimmune DiseasesDiabetes Mellitus

Interventions

Cholecalciferol

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic DiseasesImmune System DiseasesGlucose Metabolism DisordersMetabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Thomas R Pieber, Prof.

    Medical University of Graz

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 24, 2010

First Posted

November 25, 2010

Study Start

November 1, 2009

Primary Completion

June 1, 2010

Study Completion

June 1, 2010

Last Updated

February 9, 2012

Record last verified: 2012-02

Locations